In a significant stride towards advancing cancer research and drug development, Oncolines, has officially received the keys to its new laboratories and offices situated within the prestigious Curie Building on the Pivot Park in Oss, the Netherlands.
Earlier this week our colleague Nicole Willemsen-Seegers officially opened the laboratories by cutting a ribbon covering the Oncolines logo at the entry of the building. To celebrate that joyful fact, Symeres’ Head of Corporate Development Frank Leemhuis brought cake for the Oncolines crew, and he was given a tour of the labs.
The seamless transition, completed within a mere week, marks a pivotal moment in Oncolines’ journey towards pioneering breakthroughs in oncology. With this relocation, Oncolines aims to bolster its research capabilities and foster collaborations within the vibrant scientific community housed within the Curie Building which also houses other leading pharma companies like Organon and Acerta Pharma B.V.
The swift completion of the move underscores Oncolines’ commitment to operational efficiency and uninterrupted progress in its mission to develop novel therapies for cancer treatment. Despite the logistical challenges posed by the relocation, the dedicated teams at Oncolines ensured a seamless transition, with all laboratories and offices now fully operational.
The Curie Building is located at the Pivot Park in Oss, one of Europe’s foremost biopharmaceutical campuses. It is a compact 9-storey building, offering plenty of light and easy adaptation to tenants’ needs. It has a central meeting hub and office spaces, customized laboratories, and communal facilities.
The Curie is ready to accommodate about 350 people from six companies working at the intersection of science and entrepreneurship. Colloquially, and affectionately, known as Grizzly, the two-year building project saw more than 50 subcontractors, 200 companies, and almost 500 people collaborating to realize this prestigious project.
